Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Zeprumetostat is an inhibitor of enhancer of zeste homolog 2 (EZH2; IC50 = 0.87 nM for the wild-type enzyme).1 It is selective for EZH2 over a panel of 24 histone and DNA methyltransferases (IC50s = >10,000 nM for all) but also inhibits EZH1 (IC50 = 19.1 nM). Zeprumetostat also inhibits the EZH2 mutants EZH2Y641C, EZH2Y641F, EZH2Y641N, EZH2Y641S, and EZH2Y641G (IC50s = 16.8, 2.68, 1.79, 5.07, and 1.13 nM, respectively). It reduces the levels of trimethylated lysine 27 on histone H3 (H3K27Me3) in Pfeiffer diffuse large B cell lymphoma (DLBCL) cells (IC50 = 1.63 nM) and induces cell cycle arrest at the G1phase and apoptosis in the same cells. Zeprumetostat (60 and 120 mg/kg), in combination with HBI 8000 (chidamide; Item No. 13686), reduces tumor growth in patient-derived xenograft (PDX) mouse models of DLBCL.
WARNING This product is not for human or veterinary use.
1. The synergistic anti-